Trial Profile
A phase I study to investigate the safety of TEG001 cell suspension for infusion in patients with relapsed/refractory Acute Myeloid Leukemia, high-risk Myelodysplastic Syndrome (IPSS-R score >4,5) or Multiple Myeloma
Status:
Not yet recruiting
Phase of Trial:
Phase I
Latest Information Update: 01 Aug 2021
Price :
$35
*
At a glance
- Drugs TEG-001 (Primary)
- Indications Acute myeloid leukaemia; Multiple myeloma; Myelodysplastic syndromes
- Focus Adverse reactions
- 03 Aug 2017 New trial record